Valuation: GENFIT

Market Cap 51Cr 58Cr 47Cr 44Cr 82Cr 5.44TCr 84Cr 560.51Cr 216.89Cr 2.69TCr 216.67Cr 211.94Cr 9.33TCr P/E 2025
-3.06x
P/E 2026 * 53.4x
Enterprise Value 45Cr 51Cr 42Cr 39Cr 73Cr 4.85TCr 75Cr 499.89Cr 193.43Cr 2.4TCr 193.23Cr 189.01Cr 8.32TCr EV / Sales 2025
2.34x
EV / Sales 2026 * 4.82x
Free-Float
86.88%
Yield 2025 *
-
Yield 2026 * -
1 month-4.79%
3 months-6.62%
6 months+71.20%
Current year+64.13%
1 month 8.74
Extreme 8.74
9.18
Current year 5.2
Extreme 5.205
9.36
1 year 3.19
Extreme 3.19
9.36
3 years 3.19
Extreme 3.19
9.36
5 years 3.19
Extreme 3.19
9.36
10 years 3.19
Extreme 3.19
9.36
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 58Cr
-0.48%+7.20%-5.08%+2.45% 4.62TCr
+2.19%+11.71%+385.81%+632.13% 3.87TCr
+2.53%+13.93%+20.85%-10.61% 3.19TCr
+1.65%+3.61%+9.98%+55.42% 3.11TCr
-4.16%-2.58%+8.74%+15.22% 2.38TCr
-0.32%+12.96% - - 1.62TCr
+1.37%+14.53%+71.80%+134.14% 1.51TCr
+1.00%+10.30%+13.31%+22.84% 1.37TCr
+3.63%+9.53%+104.07%+107.62% 1.34TCr
Average +0.74%+9.14%+76.18%+119.90% 2.56TCr
Weighted average by Cap. +0.75%+8.71%+86.69%+140.75%

Financials

2025 2026 *
Net sales 6.68Cr 7.62Cr 6.16Cr 5.77Cr 11Cr 718.85Cr 11Cr 74Cr 29Cr 355.28Cr 29Cr 28Cr 1.23TCr 9.52Cr 11Cr 8.77Cr 8.22Cr 15Cr 1.02TCr 16Cr 105.47Cr 41Cr 506.18Cr 41Cr 40Cr 1.76TCr
Net income -83.02L -94.69L -76.53L -71.65L -1.34Cr -89Cr -1.37Cr -9.2Cr -3.56Cr -44Cr -3.56Cr -3.48Cr -153.07Cr 1.83Cr 2.09Cr 1.69Cr 1.58Cr 2.96Cr 196.95Cr 3.02Cr 20Cr 7.85Cr 97Cr 7.84Cr 7.67Cr 337.52Cr
Net Debt -5.47Cr -6.24Cr -5.04Cr -4.72Cr -8.85Cr -588.72Cr -9.04Cr -61Cr -23Cr -290.96Cr -23Cr -23Cr -1.01TCr -4.69Cr -5.35Cr -4.32Cr -4.04Cr -7.58Cr -504.23Cr -7.74Cr -52Cr -20Cr -249.2Cr -20Cr -20Cr -864.13Cr
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
188
Trader
Investor
Global
Quality
ESG MSCI
-